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Background: The synthetic glucocorticoid dexamethasone (DEX) is commonly used to prevent chronic lung
disease in prematurely born infants. Treatment regimens usually consist of high doses of DEX for several weeks,
notably during a critical period of brain development. Therefore, there is some concern about adverse effects of
this clinical practice on fetal brain development. In this study, using a clinically relevant rat model, we examined the
impact of neonatal DEX treatment on subsequent brain injury due to an episode of cerebral hypoxia-ischemia (HI).
Results: We found that a 3-day tapering course (0.5, 0.3 and 0.1 mg/kg) of DEX treatment in rat pups on postnatal days
1–3 (P1-3) exacerbated HI-induced brain injury on P7 by a glucocorticoid receptor-mediated mechanism. The
aggravating effect of neonatal DEX treatment on HI-induced brain injury was correlated with decreased glutamate
transporter-1 (GLT-1)-mediated glutamate reuptake. The expression levels of mRNA and protein of GLT-1 were
significantly reduced by neonatal DEX treatment. We also found that the administration of β-lactam antibiotic
ceftriaxone increased GLT-1 protein expression and significantly reduced HI-induced brain injury in neonatal
DEX-treated rats.
Conclusions: These results suggest that early DEX exposure may lead the neonatal brain to be more vulnerable to
subsequent HI injury, which can be ameliorated by administrating ceftriaxone.Background
Chronic lung disease (CLD) is an important cause of mor-
tality and morbidity in preterm infants and inflammation
plays a major role in its pathogenesis [1,2]. Due to their
strong anti-inflammatory properties, synthetic glucocorti-
coids such as dexamethasone (DEX) or betamethasone are
frequently used to prevent or lessen the morbidity of CLD
in preterm infants. Given that the brain is a major
target for glucocorticoids and the developing brain is
inherently more susceptible to drug-induced alterations
than the adult brain [3], there is concern that neonatal
DEX therapy may be associated with increased risk of
adverse neurologic outcomes in later life. While there
are some controversies about its adverse effects on
neurodevelopment, numerous clinical studies have demon-
strated that premature infants receiving DEX therapy have
a higher incidence of neuromotor dysfunction and an* Correspondence: richard@mail.ncku.edu.tw
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reproduction in any medium, provided the orincreased risk of developing cerebral palsy (CP) [4-7].
There is also experimental evidence that DEX exposure in
the neonatal rat pups can lead to alterations in hippocam-
pal synaptic plasticity and deficits in learning and memory
[8-10]. Although these results highlight the adverse conse-
quences of neonatal DEX treatment on brain development,
little is known about the molecular mechanisms behind
these abnormalities.
Neonatal hypoxia-ischemia (HI) is a leading cause of
perinatal brain injury, which may ultimately lead to CP,
mental retardation, learning disability and epilepsy [11].
Using different neonatal rat models of HI, previous stud-
ies have revealed that HI-induced brain injury is associ-
ated with excitotoxicity, a type of neuronal death
triggered by overstimulation of glutamate receptors and
loss of calcium homeostasis [12,13]. Interestingly, there
is evidence that pretreatment of neonatal rats with DEX
prevents brain injury associated with cerebral HI
[14-16]. These findings contrast with clinical observa-
tions that early DEX administration in preterm infants
may increase the incidence of CP [4-6]. These seemingly
discrepant findings are likely related to variations inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to perform a detailed analysis of the influence of neo-
natal DEX treatment on subsequent HI-induced brain
injury by using a protocol resembling the one used in
clinical practice for preterm infants. In this study, using
a well established and clinically relevant 3-day tapering
course of DEX treatment in neonatal rat pups on post-
natal days 1–3 (P1-3) [9,14,17,18], we asked two main
questions: (1) whether neonatal DEX treatment alters
the vulnerability of the immature brain to HI-induced
brain injury and (2) if so, what is the responsible mo-
lecular mechanism(s).
Results
Neonatal DEX treatment enhances HI-induced brain injury
To determine the influence of neonatal DEX treatment
on HI-induced brain injury, we compared the infarction
areas in coronal sections of SAL and DEX groups 24
hours after experimental HI (Figure 1A). We chose this
time point because it has been reported to be the peak
in expression of neonatal HI-induced cell damage [19].Figure 1 Effect of neonatal DEX treatment on HI-induced brain injury
examining the effect of neonatal DEX treatment on subsequent HI-induced
(0.5, 0.3 and 0.1 mg/kg) of DEX or equal volume of SAL from P1 to P3 and
common carotid artery followed by exposure to hypoxia (92% N2 + 8% O2)
(left column) and Nissl staining (right column) of serial coronal sections 24
(white areas), particularly in the ipsilateral cerebral cortex and the hippocam
quantified at 24 hours after HI by TTC staining. Sham denotes animals rece
to normoxic condition. (D) Fluorescent TUNEL staining (TUNEL-positive cell
TUNEL labeling of apoptotic cells in the frontal cortex of neonatal SAL- or
another four rat pups in each group. Scale bar is 100 μm. The numbers in
presented as means ± S.E. M.Figure 1B shows representative images from HI rats
stained with 2,3,5-triphenyltetrazolium chloride (TTC) or
cresyl violet. Neonatal DEX-treated group exhibited more
severe HI-induced brain injury, particularly in the cerebral
cortex and the hippocampus, than SAL-treated group.
One-way ANOVA revealed a significant main effect of HI
treatment on infarct volume (F3,25 = 15.3, P < 0.001), and
post hoc analysis showed that infarct volume was signifi-
cantly increased (P < 0.05) by neonatal DEX treatment
compared with SAL-treated group (Figure 1C). The en-
hancement effect of neonatal DEX treatment on HI-
induced brain injury was prevented when the animals were
given glucocorticoid receptor (GR) antagonist, RU 38486
(40 mg/kg), 1 hour before daily DEX treatment (P < 0.05
vs. DEX). TUNEL analysis was used to determine whether
neonatal DEX treatment may sensitize HI-induced cell
damage. As shown in Figure 1D, TUNEL-positive apop-
totic cells were evident within the frontal cortex ipsilateral
to common carotid artery ligation 24 hours after HI. The
number of TUNEL-positive cells was significantly greater
in DEX-treated group than saline-treated group.. (A) Schematic representation of the experimental design for
brain injury. Rat pups were treated with a 3-day tapering course
were subjected to cerebral HI by unilateral ligation of the right
for 2 hours on P7. Brain injury was analyzed on P8. (B) TTC
hours after HI. DEX-treated group exhibited more marked infarctions
pus, than SAL-treated group. Scale bar is 0.5 cm. (C) Brain injury was
ived right carotid artery exposure without ligation and were exposed
s are green) with DAPI counterstain (blue) was utilized to visualize
DEX-treated rat pups 24 hours after HI. Similar results were observed in
parentheses indicate the number of animals examined. Data are
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glutamate reuptake
Because excitotoxicity due to excessive extracellular glu-
tamate is closely associated with HI-induced brain injury
[12,13] and transporter-mediated glutamate uptake is es-
sential for maintaining low extracellular glutamate con-
centrations [20], we therefore examined the influence of
neonatal DEX treatment on basal glutamate uptake activ-
ity in gliosomes from the frontal cortex on P7. The
amounts of total and GLT-1-mediated glutamate uptake
in gliosomes were significantly reduced in DEX-treated
group compared with SAL-treated group (Total: F1,8 =
28.3; P < 0.001; GLT-1: F1,8 = 9.8; P = 0.014; Figure 2). Al-
though the amount of non-GLT-1-mediated glutamate up-
take tended to be lower in DEX-treated group compared
with that from SAL-treated group, the difference did
not reach statistical significance (F1,8 = 3.7; P = 0.08). In
addition, the observed reduction in basal glutamate uptake
activity in DEX-treated group was prevented when rat
pups were given RU 38486 (40 mg/kg) 1 hour before daily
DEX treatment (F1,14 = 21.7; P < 0.001; data not shown).
Neonatal DEX treatment decreases basal GLT-1 and
GLAST mRNA and protein expression
So far, five distinct mammalian glutamate transporter sub-
types, termed EAAT1 (glutamate-aspartate transporter,
GLAST), EAAT2 (GLT-1), EAAT3 (excitatory amino acid
carrier 1, EAAC1), EAAT4 and EAAT5, have been cloned.
GLAST and GLT-1 are found predominantly in glial cells
and EAAC1 is expressed in both neurons and glial cells
[21]. Because the observed reduction of glutamate uptakeFigure 2 Effect of neonatal DEX treatment on glutamate
uptake activity in gliosomes. Summary bar graphs depicting
glutamate uptake activity in gliasomes from the frontal cortex of
SAL- and DEX-treated groups on P7. DEX-treated group exhibited a
significant decrease of total, and GLT-1-mediated glutamate uptake
compared with those of SAL-treated group. The non-GLT-1-mediated
glutamate uptake was calculated in the presence of GLT-1 inhibitor
dihydrokainate (100 μM). The numbers in parentheses indicate the
number of animals examined. Data are presented as means ± S.E.M.
*P < 0.05 compared with SAL-treated group.in DEX-treated group could be a result of decreased ex-
pression of glutamate transporters, we therefore examined
the influence of neonatal DEX treatment on the expres-
sion of basal glutamate transporters in the frontal cortex
on P7. Quantitative real-time RT-PCR analysis showed
that neonatal DEX treatment led to decreased expression
of GLT-1 (F1,11 = 14.7; P < 0.01) and GLAST mRNAs
(F1,13 = 15.5; P < 0.01) compared with SAL-treated group
(Figures 3A and B). The observed reduction in GLT-1 and
GLAST mRNA expression in DEX-treated group was
prevented when rat pups were given RU 38486 (40 mg/kg)
1 hour before daily DEX treatment (P < 0.05 vs. DEX).
However, there was no significant difference between
DEX- and SAL-treated group in EAAC1 mRNA expres-
sion (F1,14 = 0.2; P = 0.63). In parallel, the levels of GLT-1
and GLAST proteins in the frontal cortex were noted to
be decreased in DEX-treated group compared with SAL-
treated group on P7 (GLT-1: F1,26 = 47.3; P < 0.001;
GLAST: F1,11 = 13.1; P < 0.01; Figures 4A and B). The in-
hibitory effect of neonatal DEX treatment on GLT-1 and
GLAST protein expression was prevented when the ani-
mals were given RU 38486 (40 mg/kg) 1 hour before daily
DEX treatment (P < 0.05 vs. DEX).
On the basis of the data demonstrating the down-
regulation of GLT-1 and GLAST protein levels after neo-
natal DEX treatment, it was assumed that reduced GLT-1
and GLAST protein levels may contribute to enhanced
HI-induced brain injury by neonatal DEX treatment. To
test this possibility, we ran a correlation between them in
slices prepared from DEX-treated group. A clear inverse
correlation was found between the extent of TTC-defined
infarct volume 24 hours after HI and the relative levels of
GLT-1 protein (r = −0.55; P = 0.03, n = 15; Figure 4C). In
contrast, no such relationship was seen with the relative
levels of GLAST protein (r = −0.02; P = 0.96, n = 12;
Figure 4D).
DEX treatment decreases GLT-1 mRNA and protein
expression in C6 glioma cells
As GLT-1 is expressed predominantly in glial cells [20],
further experiments were performed to determine whether
DEX treatment may downregulate the expression of GLT-
1 in glial cell cultures in vitro. To test this possibility, rat
C6 glioma cells were treated with DEX (100 μM) for 24
and 48 hours, respectively. As expected, GLT-1 protein ex-
pression in C6 glioma cells was significantly downregulated
by DEX treatment, based on Western blotting analysis of
whole-cell lysates (24 hours: F1,18 = 12.8; P < 0.01; 48 hours:
F1,18 = 5.2; P < 0.05; Figure 5A). In contrast, GLAST
protein expression was not altered by DEX treatment (24
hours: F1,18 = 0.2; P = 0.67; 48 hours: F1,18 = 0.1; P = 0.89;
Figure 5B). In parallel, a significant decrease in GLT-1
mRNA expression was noted in C6 glioma cells of
DEX-treated group compared with vehicle-treated group
Figure 3 Effect of neonatal DEX treatment on the expression of
glutamate uptake transporter mRNAs in the frontal cortex.
(A-C) Quantitative real-time PCR analysis showing the relative
expression levels of GLT-1 (A), GLAST (B), and EAAC1 (C) mRNA in
the frontal cortex from SAL-, DEX-, vehicle (Veh)- and DEX + RU
38486 (RU)-treated groups on P7. The vehicle group received
equivalent volume of intraperitoneal injection of propylene glycol.
The numbers in parentheses indicate the number of animals
examined. Data are presented as means ± S.E.M. *P < 0.05 compared
with SAL-treated group.
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0.05; Figure 5C), whereas GLAST mRNA level was not al-
tered by DEX treatment (24 hours: F1,18 = 1.1; P = 0.31; 48
hours: F1,18 = 0.1; P = 0.86; Figure 5D).
The expression of N-methyl-D-aspartate receptors is not
alter by neonatal DEX treatment
The occurrence of HI-induced excitotoxicity is generally
thought to be associated with overstimulation of glutam-
ate receptors, particularly the N-methyl-D-aspartate
(NMDA) receptor subtype [12,13]. Hence, we determined
whether the expression levels of NMDA receptor in the
frontal cortex were altered by neonatal DEX treatment. As
shown in Figures 6A-C, there were no significant differ-
ences between DEX- and SAL-treated group in the ex-
pression levels of the two major NMDA receptor
subunits, NR2A and NR2B, in the whole tissue lysates of
the frontal cortex on P7 (NR2A: F1,14 = 0.6; P = 0.45;
NR2B: F1,14 = 1.2; P = 0.29).
Ceftriaxone attenuates HI-induced brain injury in
neonatal DEX-treated rat pups
The above results clearly indicate the importance of GLT-
1 levels in determining the vulnerability of the neonatal
brain to HI injury. These findings prompted us to investi-
gate whether the elevation of GLT-1 protein expression
could attenuate the reinforcing effect of neonatal DEX
treatment on HI-induced brain injury. For this, neonatal
rat pups were pretreated with β-lactam antibiotic ceftriax-
one (200 mg/kg), that have been shown to effectively exert
neuroprotective effect against neonatal HI-induced brain
injury through the elevation of GLT-1 expression [22], 1
hour before DEX application (Figure 7A). As expected, we
observed that ceftriaxone treatment significantly reduced
HI-induced brain injury (F1,26 = 5.1; P < 0.05 vs. SAL)
and attenuated the extent of brain damage in DEX-
treated rat pups to HI (F1,21 = 6.5; P < 0.05 vs. DEX;
Figure 7B). In addition, ceftriaxone treatment substan-
tially increased GLT-1 protein expression in the frontal
cortex (F1,6 = 13.1; P < 0.01 vs. SAL; Figure 7C), the hippo-
campus (F1,6 = 6.2; P < 0.05 vs. SAL; Figure 7D) and the
striatum (F1,6 = 9.7; P < 0.05 vs. SAL; Figure 7E), and com-
pletely rescued the inhibitory effect of DEX treatment on
GLT-1 protein expression in the frontal cortex (F1,8 = 9.6;
P < 0.05 vs. DEX; Figure 7C) and the hippocampus (F1,6 =
7.2; P < 0.05 vs. DEX; Figure 7D). In contrast, GLT-1
protein expression in the striatum was not significantly af-
fected by neonatal DEX treatment (F1,6 = 0.9; P = 0.39 vs.
SAL; Figure 7E).
Discussion
The concern that neonatal DEX therapy might increase
risk of developing neurological dysfunction by altering
neural development was an important motivation for
Figure 4 Effect of neonatal DEX treatment on the expression of glutamate uptake transporter proteins in the frontal cortex. (A and B)
Representative Western blot and summary bar graph depicting the relative expression levels of GLT-1 (A) and GLAST protein (B) in the frontal
cortex from SAL-, DEX-, vehicle (Veh)- and DEX + RU 38486 (RU)-treated groups on P7. (C) A significant inverse correlation was found between
the extent of TTC-defined infarct volume 24 hours after HI and the relative levels of GLT-1 protein. (D) The extent of TTC-defined infarct volume
24 hours after HI was not correlated with the relative levels of GLAST protein. The numbers in parentheses indicate the number of animals
examined. Data are presented as means ± S.E.M. *P < 0.05 compared with SAL-treated group.
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results provide the first evidence that neonatal DEX
treatment leads to a sustained downregulation of GLT-1
expression and thereby exacerbates HI-induced brain in-
jury. Moreover, we confirm that ceftriaxone can exert a
neuroprotective effect against HI-induced brain injury in
neonatal rats by increasing expression of GLT-1 [22] and
suggest that pretreatment with ceftriaxone in neonatal
rats can effectively attenuate DEX-induced augmentation
of HI-induced brain injury.
Excitotoxicity related to extracellular accumulation of
glutamate plays a critical role in neonatal HI-induced brain
injury [23]. The accumulation of extracellular glutamate
may result from either decreased uptake or the reversed ac-
tion of glutamate transporters [20]. The observation that
DEX-treated group showed a significantly lower GLT-1-me-
diated glutamate uptake activity in gliosomes compared
with that from SAL-treated group suggests that neonatal
DEX treatment may cause decreased glutamate uptake and
result in deleterious enhancement of excitotoxic brain in-
jury to subsequent HI insults. In addition, we observed that
neonatal DEX treatment led to a significant decrease in
both mRNA and protein levels of GLT-1 and GLAST, indi-
cating that reduced expression of glutamate transportersmay account, at least in part, for the decrease in glutamate
uptake observed in P7 rat pups. It is however noteworthy
that, although expression levels of both GLT-1 and GLAST
were downregulated by neonatal DEX treatment, we
observed no significant correlation between the extent of
HI-induced brain injury and the expression of GLAST pro-
tein. In contrast, our results revealed that GLT-1 protein
levels are inversely correlated with the extent of HI-induced
brain injury. Therefore, we hypothesize that changes in
GLT-1 protein expression underlie the enhancement of
neonatal HI-induced brain injury found in DEX-treated
rats. This hypothesis is further supported by findings that
ceftriaxone treatment attenuates the enhancing effect of
neonatal DEX treatment on HI-induced brain injury by in-
creasing GLT-1 expression. Moreover, we found no signifi-
cant differences in expression of NR2A and NR2B subunits
in the frontal cortex between DEX- and SAL-treated
groups, suggesting that neonatal DEX treatment does not
alter the total amount of NMDA receptors.
How does neonatal DEX treatment lead to a lasting de-
crease in GLT-1 expression? Our finding that administration
of RU 38486 almost completely prevented DEX-induced de-
creases in GLT-1 mRNA and protein expression supports a
pathway involving the GR. Although the molecular basis of
Figure 5 Effect of DEX treatment on the expression of glutamate uptake transporter proteins and mRNAs in C6 glioma cells. (A and B)
Representative Western blot and summary bar graph depicting the relative expression levels of GLT-1 (A) and GLAST protein (B) in C6 glioma
cells treated with either vehicle (Veh, 0.1% DMSO) or DEX (100 μM) for 24 or 48 hours. (C and D) Quantitative real-time PCR analysis showing the
relative expression levels of GLT-1 (C) or GLAST mRNA (D) in C6 glioma cells treated with either Veh or DEX (100 μM) for 24 or 48 hours. The
numbers in parentheses indicate the number of animals examined. Data are presented as means ± S.E.M. *P < 0.05 compared with
Veh-treated group.
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mains unclear, it is highly likely that GR acts mainly
through interfering with the nuclear transcription factor
nuclear factor-κB (NF-κB) signaling to downregulate
GLT-1 expression. Using either pharmacological or genetic
approaches, the NF-κB signaling has been linked to several
drug-induced or neuron-dependent transcriptional activa-
tion of GLT-1 [24-26]. Thus, downregulation of NF-κB
activity could be associated with a decrease in GLT-1 gene
transcription. It has been observed in multiple cell types
that DEX can inhibit NF-κB activation by enhancing the
cellular levels of IκB-α [27,28] or the protein-protein inter-
action between activated GR and the p65 NF-κB subunit
[29,30]. Thus, it is reasonable to speculate that DEX
may act indirectly by inhibiting NF-κB activity and subse-
quently decreasing GLT-1 transcription. However, we
could not exclude the possibility that DEX may inhibit
transcriptional activation of GLT-1 through a direct DNA
binding of activated GR to a specific site in the GLT-1
promoter. Further studies are required to test these
possibilities.
We observed that DEX treatment decreases the ex-
pression of GLT-1 mRNA and protein in C6 glioma cells
in vitro, consistent with our finding in vivo showing thereduction in GLT-1 expression in the frontal cortex by
neonatal DEX treatment. However, this finding is in con-
trast with observations made in a previous study, which
reported that DEX provokes an increase of GLT-1 tran-
scription and protein levels in cortical astrocytes [31]. The
reason for this seemingly contradictory finding is unclear
but may be related to differences in experimental design as
well as differences in cell types. Zschocke et al. [31] used
rat primary cortical astrocytes and examined the extent of
GLT-1 induction 72 hours after DEX (100 nM) treatment,
whereas the present study examined the expression of
GLT-1 in rat C6 glioma cells that were treated with DEX
(100 μM) for 24–48 hours. Interestingly, as opposed to
GLT-1, expression levels of GLAST mRNA and protein
GLAST were not altered by DEX treatment in C6 glioma
cells. These observations suggest that these two glial glu-
tamate transporter subtypes have different sensitivities to
glucocorticoid treatment. Further studies using different
dosages of DEX are required to address this issue.
Because glucocorticoid therapy significantly reduces
the incidence of CLD [17], it is difficult to avoid its use
during neonatal life in preterm infants. There are two
ways to reduce its adverse effects. One way is by lowing
the DEX dosage or decreasing the duration of treatment
Figure 6 Effect of neonatal DEX treatment on the expression of
NMDA receptor subunit proteins in the frontal cortex. (A-C)
Representative Western blot (A) and summary bar graph depicting
the relative expression levels of NR2A (B) and NR2B subunit protein
(C) in the frontal cortex from SAL- and DEX-treated groups on P7.
The numbers in parentheses indicate the number of animals
examined. Data are presented as means ± S.E.M.
Chang et al. Molecular Brain 2013, 6:18 Page 7 of 11
http://www.molecularbrain.com/content/6/1/18and another way is in combination with other drugs. In
the present study, our data revealed the potential clinical
benefit of ceftriaxone to ameliorate DEX-induced po-
tentiation of HI-induced brain injury. These results are
in agreement with recent studies that ceftriaxone can
offer neuroprotection in both in vitro and in vivo models
of ischemic injury and motor neuron degeneration by
preventing glutamate excitotoxicity [22,32]. Recent re-
ports have also established that ceftriaxone may exert itsneuroprotective effects by inducing GLT-1 transcription
through increasing NF-κB binding to the GLT-1 promoter
[25,33]. Although ceftriaxone has FDA approved for use
in pediatric bacterial meningitis for a long time, there was
no evidence of long-term neurodevelopmental sequelae of
ceftriaxone treatment in the neonate. Our findings with
ceftriaxone suggest that adjunct neuroprotective therapies
that elevate GLT-1 activity may minimize glutamate
excitotoxicity, thereby allowing a choice of DEX for use in
neonates. Further large trials in humans are needed to
confirm these results.
Perinatal HI-induced brain injury is one of major causes
of CP. There is increasing evidence showing that early
DEX administration in preterm infants may increase the
incidence of CP [4-6]. In accordance with these clinical
findings, the current results show that early DEX exposure
is able to increase the vulnerability of the neonatal brain
to subsequent HI damage. Although there are some stud-
ies indicating that DEX pretreatment can protect neonatal
brain against subsequent HI injury [15,16,34], our results
do not support a neuroprotective role for neonatal DEX
treatment in cerebral HI. One possible explanation of
these seemingly discrepant observations is the different
doses and regimens of DEX used among studies. These
findings reinforce the long-held view that the concentra-
tion and duration of glucocorticoid treatment are major
factors determining the beneficial or detrimental effects of
glucocorticoids in the brain [35]. In our model, DEX was
administered over a long period (P1-3) in tapering doses
in an attempt to mimic the longer treatment regimens
commonly used in the neonatal intensive care setting
[8,9,14,17,18]. While much caution is required when
extrapolating data from animal models to the human con-
dition, our findings highlight the risk for heightened devel-
oping brain vulnerability to HI injury associated with
neonatal DEX treatment.
Conclusion
In conclusion, our data provide evidence for a deleteri-
ous impact of neonatal DEX treatment on HI injury in
the developing brain. Pretreatment wit ceftriaxone, per-
haps due to an increase in GLT-1 expression, is able to
stimulate glutamate uptake and overcome the excessive
HI-induced brain injury resulting from neonatal DEX
treatment. Although further investigations are needed to
elucidate the molecular mechanisms involved in the GR-
mediated downregulation of GLT-1 transcription, our
findings demonstrate that supporting GLT-1 expression
may exert beneficial effects to ameliorate the lasting en-
hancing effect of neonatal DEX treatment on glutamate-
mediated excitotoxicity. These findings are of clinical
importance because it is now difficult to avoid the use of
corticosteroids in neonatology and perinatology to fight
the problems of CLD.
Figure 7 Ceftriaxone attenuates HI-induced brain injury and the loss of GLT-1 protein in neonatal DEX-treated rats. (A) Schematic
representation of the experimental design for examining the effect of ceftriaxone (CEF) treatment on DEX-induced enhancement of HI-induced
brain injury. Rat pups were treated with a 3-day tapering course (0.5, 0.3 and 0.1 mg/kg) of DEX or equal volume of SAL from P1 to P3 and were
subjected to cerebral HI by unilateral ligation of the common carotid artery followed by exposure to hypoxia (92% N2 + 8% O2) for 2 hours on P7.
Ceftriaxone (200 mg/kg) was injected intraperitoneally 1 hour before DEX or SAL administration. Brain injury and the expression of GLT-1 protein
in the frontal cortex were analyzed on P8. (B) Brain injury was quantified at 24 hours after HI by TTC staining. (C-E) Representative Western blot
and summary bar graph depicting the relative expression levels of GLT-1 in the frontal cortex (C), the hippocampus (D) and the striatum (E) from
SAL-, DEX-, SAL + CEF- and DEX + CEF-treated groups on P7. The numbers in parentheses indicate the number of animals examined. Data are
presented as means ± S.E.M. *P < 0.05 compared with SAL-treated group.
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Animals
Pregnant Sprague–Dawley rats (body weight 250–280 g)
were single-housed under controlled illumination (12/12-
hour light–dark cycle) and ambient temperature (24°C),
and had ad libitum access to food and water. Pups were
born on days 22–23 of gestation. On the day of birth (des-
ignated day 0), pups were removed from the nests and
eight healthy pups (four males and four females) were ran-
domly placed back with each dam. All experimental pro-
cedures were performed according to the National
Institutes of Health Guide for the Care and Use of Labora-
tory Animals and were approved by the Institutional
Animal Care and Use Committee of National Cheng
Kung University.Cell culture
Rat C6 glioma cells were obtained from American Type
Culture Collection (Manassas, VA) and cultured essentially
as described by Amberger et al. [36]. Cells were cultured in
6 cm dishes in Dulbecco’s modified Eagle medium (DMEM;
Invitrogen, San Diego, CA) supplemented with 10% fetal
bovine serum (Invitrogen, Gaithersburg, MD), 2 mM L-
glutamine, and penicillin (100 U/ml)/streptomycin (100 μg/
ml) and incubated in 5% CO2-air humidified atmosphere at
37°C. Thereafter, half of the growth medium was replaced
every three days. After cells reached ∼ 80% confluence, ve-
hicle (0.1% DMSO) or DEX (100 μM) was added to the
medium, and the plates were returned to the incubator until
the assay was performed. The dose and duration of DEX
treatment were selected on the basis of our pilot studies.
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Each litter was assigned to two treatment groups: a SAL-
treated and DEX-treated group. All pups within each litter
were removed from their home cage and separated from
their mother for injection and body weight measurement
(between 11:00 and 13:00) for a period of 5 minutes. Only
male offspring were used for experiments. Pups in the
DEX group received a daily intraperitoneal injection of
DEX (Sigma-Aldrich, St. Louis, MO) from P1 to P3. DEX
was given in tapering doses of 0.5 mg/kg on P1, 0.3 mg/kg
on P2, and 0.1 mg/kg on P3. Animals in the vehicle group
received equivalent volumes of intraperitoneal injection of
sterile SAL as the DEX-treated group. In some experi-
ments, RU 38486 (40 mg/kg; Tocris Cookson Ltd., Bristol,
UK) or ceftriaxone (200 mg/kg; Sigma-Aldrich) was ad-
ministered intraperitoneally 1 hour before daily DEX ap-
plication. Doses of RU 38486 and ceftriaxone were
selected on the basis of previously published and our pilot
studies [21,37]. Animals in the vehicle group received
equivalent volumes of intraperitoneal injection of propyl-
ene glycol.
Production of cerebral hypoxia-ischemia (HI)
Cerebral HI was produced as described previously [34].
Briefly, rat pups at P7 were anesthetized with halothane
and underwent the right common carotid artery ligation
through a longitudinal midline neck incision. The incision
site was infiltrated with 2% lidocaine and the surgery
lasted less than 5 minutes. The rat pups were returned to
home cage with their dam for 3 hours followed by expos-
ure to hypoxia (8% oxygen/92% nitrogen at 37°C) for 2
hours in a temperature-controlled plastic chamber. Sham
animals underwent anesthesia and neck incision, the ca-
rotid artery was exposed without the ligation and was ex-
posed to normoxic condition. The pups were returned to
their dam after the hypoxic exposure.
Assessment of infarct volume
Twenty-four hours after HI, rat pups were deeply anesthe-
tized with isoflurane. The brains were removed carefully
and dissected into coronal 2 mm sections using Leica
VT1200S vibrating blade microtome (Leica, Nussloch,
Germany). The slices were incubated in 2% TTC solution
for 5 minutes in the dark, washed in phosphate buffered
saline, and fixed in 10% formaldehyde. The infarct volume
was traced and analyzed with Image J Software. The total
infarct volume for each brain was calculated by summa-
tion of the infarcted area of all brain slices.
Histochemical analysis
Twenty-four hours after HI, rat pups were deeply anesthe-
tized with isoflurane and perfused transcardially with 0.1
M phosphate buffered saline (PBS) and 4% paraformalde-
hyde. After the perfusion, brains were removed andcontinue to fix in 4% paraformaldehyde for 48 hours at 4°C
and then transferred to the solution containing 30% su-
crose that immersed in 4°C for at least 48 hours before sli-
cing. Coronal brain sections (25 μm) were collected,
washed with 0.3% Triton X-100, and then incubated for
blocking with solution containing 3% goat serum in PBS.
The sections were mounted directly on gelatin-coated glass
slides and dried. The slides were stained with 1.0% cresyl
violet, dehydrated through a series of ethanol, cleared, and
coverslipped with permount (Fisher Scientific, Electron
Microscopy Sciences, Washington, PA). Stained sections
were then examined under a computer-assisted Olympus
BX51 microscope and images were taken with an Olympus
DP70 microscope digital camera (Olympus, Tokyo, Japan).
TUNEL analysis
Twenty-four hours after HI, rat pups were deeply anesthe-
tized with isoflurane and Coronal brain sections (10 μm)
were prepared as described above. The presence of apop-
totic cells in the frontal cortex was detected by fluorometric
detection of DNA fragmentation using an ApopTagW Fluor-
escein In Situ Apoptosis Detection Kit (S7110, Millipore,
Bedford, MA) according to the manufacturer instructions.
Slices were mounted using Vectashield mounting medium
containing 40,6-diamidino-2-phenylindole dilactate (DAPI)
nuclear stain (Vector Laboratories, Burlingame, CA).
Preparation of gliosomes and glutamate uptake assay
The gliosomal fractions of the frontal cortex were prepared
as previously described with some modifications [38]. In
brief, the microdissected tissue samples were homogenized
in 0.32 M sucrose, 1 mM EDTA, 4 mM Tris and 10 mM
glucose, pH 7.4, using a glass-Teflon homogenizer. Homog-
enates were centrifuged at 1,000 × g for 5 minutes, 4°C.
The resultant pellet was discarded, and the supernatant was
spun at 14,000 × g for 10 minutes in a microcentrifuge, 4°C.
The pellets constituted the crude gliosomal fractions. The
crude gliosomal fractions were resuspended in Krebs-
Ringer buffer (in mM: 120 NaCl, 4.7 KCl, 2.2 CaCl2, 1.2
MgCl2, 25 HEPES, 1.2 MgSO4, 1.2 KH2PO4 and 10 glucose,
pH 7.4) to give a protein concentration of 0.5 mg/ml that
was determined by using a Pierce BCA Protein Assay Kit
(Thermo Scientific, Rockford, IL). Glutamate uptake assay
was performed as described previously [39]. Glutamate
uptake in gliosomes was initiated by adding 3H-glutamate
(10 nM, 20–60 Ci/mmol; Perkin Elmer, Boston, MA) and
30 μM unlabeled glutamate to the reaction tubes in a final
volume of 500 μl of HEPES buffer solution. After incuba-
tion at 37°C for 5 minutes, the uptake was terminated by
rapid filtration on glass-fiber filters using a tissue harvester
under vacuum, and the filter was washed five times
with ice cold HEPES buffer solution. Filters were dried
overnight and countered on a liquid scintillation counter
(Beckman Instruments, Fullerton, CA). Nonspecific uptake
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pared by replacing NaCl with choline chloride. The non-
glutamate transporter-1 (non-GLT-1)-mediated glutamate
uptake was calculated in the presence of GLT-1 inhibitor
dihydrokainate (100 μM; Sigma-Aldrich).
Western blotting
The microdissected tissue samples from the frontal cortex,
the hippocampus or the striatum were transferred into
ice-cold Tris–HCl buffer solution (TBS; pH 7.4) con-
taining a cocktail of protein phosphatase and proteinase
inhibitors (50 mM Tris–HCl, 100 mM NaCl, 15 mM so-
dium pyrophosphate, 50 mM sodium fluoride, 1 mM so-
dium orthovanadate, 5 mM EGTA, 5 mM EDTA, 1 mM
phenylmethylsulfonyl fluoride, 1 μM microcystin-LR, 1 μM
okadaic acid, 0.5% Triton X-100, 2 mM benzamidine, 60
μg/ml aprotinin, and 60 μg/ml leupeptin) to avoid dephos-
phorylation and degradation of proteins, and ground with
a pellet pestle (Kontes glassware, Vineland, NJ). In some
experiments, cultured C6 glioma cells were dissolved in
ice-cold TBS containing a cocktail of protein phosphatase
and proteinase inhibitors and collected by cell scraper.
Samples were sonicated and spun down at 15,000 × g at
4°C for 10 minutes. The supernatant was then assayed for
total protein concentration using Bio-Rad Bradford Protein
Assay Kit (Hercules, CA). Each sample from tissue hom-
ogenate was separated using 8-10% SDS-PAGE gel. Follow-
ing the transfer on nitrocellulose or polyvinylidene fluoride
membranes, blots were blocked in buffer solution
containing 5% milk and 0.1% Tween-20 in PBS (in mM:
124 NaCl, 4 KCl, 10 Na2HPO4 and 10 KH2PO4; pH 7.2)
for 1 hour and then blotted for 2 hours at room tem-
perature with antibodies that recognize GLT-1 (1:1000;
Abcam Cambridge, MA), GLAST (1:1000; Abcam). NR2A
(1:1000; Santa Cruz Biotechnology, Santa Cruz, CA),
NR2B (1:1000; Santa Cruz Biotechnology) or β-actin
(1:4000; Sigma-Aldrich, St Louis, MO). It was then probed
with HRP-conjugated secondary antibody for 1 hour and
developed using the ECL immunoblotting detection system
(Amersham Biosciences, Buckinghamshire, UK), according
to manufacturer’s instructions. Immunoblots were analyzed
by densitometry using Bio-profil BioLight PC software
(Vulber Lourmat, France). Only film exposures that were
not saturated were used for quantification analysis. Expres-
sion of GLT-1, GLAST, NR2A or NR2B was evaluated rela-
tive to that for β-actin. Background correction values were
subtracted from each lane to minimize the variability across
membranes.
Quantitative real-time RT-PCR
Total RNA was isolated from rACC tissue samples using a
Tri Reagent kit (Molecular Research Center, Cincinnati,
OH) and treated with RNase-free DNase (RQ1; Promega,
Madison, WI) to remove potential contamination bygenomic DNA. Total RNA (1 μg) from samples was reverse
transcribed using a SuperScript cDNA synthesis kit
(Invitrogen, Carlsbad, CA). Real-time PCR was performed
on the Roche LightCycler instrument (Roche Diagnostics,
Indianapolis, IN) using the FastStart DNA Master SYBR
Green I kit (Roche Applied Science) according to the man-
ufacturer’s instructions. The following primers were used:
GLT-1 (1618–1780), 50-ATTGACTCCCAACACCG-30 (for
ward) and 50-CATTGGCCGCCAGAGTTA-30 (reverse);
GLAST, 50-TATACAGTGACAGTCATCGTC-30 (forward)
and 50-ACAAATCTGGTGATGCGT-30 (reverse); excita-
tory amino acid carrier 1 (EAAC1), 50- GTCATTCTGC
CACTGATTAT-30 (forward) and 50-GATGCCGTCTG.
AGTACAG-30 (reverse); β-actin, 50-TTCTACAATGA
GCTGCGTGTGGC-30 (forward) and 50-CTCATAGCTCT
TCTCCAGGGAGGA-30 (reverse). PCR cycles consisted of
an initial denaturation step at 95°C for 10 minutes, followed
by 45 cycles of 10 seconds at 95°C, 10 seconds at 65°C, and
20 seconds at 72°C. After amplification, equal volumes of
PCR products were subjected to electrophoresis on 1.5%
(w/v) agarose gels and visualized with ethidium bromide. A
melting curve was created at the end of the PCR cycle to
confirm that a single product had been amplified. Data
were analyzed by LightCycler quantification software to de-
termine the threshold cycle above background for each re-
action. The relative transcript amount of the gene of
interest, which was calculated using standard curves of ser-
ial RNA dilutions, was normalized to that of β-actin of the
same RNA.
Data analysis
All data are expressed as means ± S.E.M. Number of ani-
mals used is indicated by n. The significance of the differ-
ence between the groups was calculated by one-way
analysis of variance followed by Fisher’s least significant
difference post hoc test. Probability values (P) of less than
0.05 were considered to represent significant differences.
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